Previous Article | Next Article ![]()
Clinical and Diagnostic Laboratory Immunology, January 2004, p. 222-226, Vol. 11, No. 1
1071-412X/04/$08.00+0 DOI: 10.1128/CDLI.11.1.222-226.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Public Health Research Institute, Newark, New Jersey,1 Merck Research Laboratories, West Point, Pennsylvania,2 Department of Comparative Medicine, Stanford University, Stanford, California ,3 Statens Serum Institute, Copenhagen, Denmark4
Received 20 August 2003/ Returned for modification 16 October 2003/ Accepted 27 October 2003
|
|
|---|
90%) of experimentally or naturally infected nonhuman primates. Here, the antibody response to ESAT-6 in tuberculous monkeys was characterized at the epitope level by measuring antibodies to overlapping, synthetic peptides spanning the ESAT-6 sequence. The antibody response against the COOH-terminal portion of the protein was the strongest in both experimentally and naturally infected animals. Moreover, these antibodies became detectable the earliest during experimental infection, suggesting an ordered expansion of ESAT-6-specific B-cell clones in the course of infection. The data support use of synthetic peptides in lieu of the full-length ESAT-6 protein in diagnostic antibody detection assays. |
|
|---|
In previous work members of our group showed that 6-kDa early secretory antigenic target (ESAT-6), a low-molecular-weight protein secreted by virulent M. tuberculosis and Mycobacterium bovis (6, 12), induced strong antibody responses in >90% of experimentally infected monkeys (1). An outbreak of M. bovis infection in a nonhuman primate research facility provided the opportunity to characterize the antibody response to ESAT-6 in naturally infected macaques. We found that almost 90% of the animals exhibiting TB lesions at necropsy had anti-ESAT-6 immunoglobulin G (IgG) antibody (7). These studies strongly imply that an antibody detection assay utilizing ESAT-6 has a place in the diagnosis of TB in nonhuman primates. The present study was conducted to further characterize the IgG antibody response to ESAT-6 at the epitope level in experimentally infected and naturally infected nonhuman primates.
Three groups of nonhuman primates were included in the study. The first comprised 11 animals (4 cynomolgus macaques, 5 rhesus macaques, and 2 African Green monkeys) infected experimentally with 100 CFU of M. tuberculosis Erdman by the intratracheal route (1). Rhesus and African Green monkeys were obtained from closed breeding colonies; cynomolgus monkeys were feral, of Mauritian origin. Experimental infection was conducted using biosafety level 3 operating procedures and policies in a biosafety level 3 facility with approval of and oversight by the Institutional Environmental Health and Safety Office. TB was confirmed at necropsy by histopathology of major organs, acid-fast or fluorescent staining of infected tissue, culture methods, and bacterial nucleic acid amplification, as previously described (1). A second group of animals included 15 naturally infected monkeys (12 cynomolgus macaques and 3 rhesus macaques). Adult male, feral cynomolgus macaques of Mauritian origin and adult male and female rhesus macaques were housed in animal holding facilities at Stanford University, which is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care. These animals, which became infected with M. bovis during an outbreak of TB in the animal facility, were confirmed to have TB at necropsy by histopathology of major organs and acid-fast staining of infected tissue (7). The infectious agent, which was isolated from characteristic lesions, was identified as M. bovis on the basis of standard methods (genotyping with the insertion sequence IS6110 [13] and resistance to pyrazinamide). A third group comprised five baboons imported from Tanzania by Worldwide Primates, Inc. (Miami, Fla.), an importer of nonhuman primates registered with the Centers for Disease Control and Prevention. These animals were confirmed to have TB based on M. tuberculosis-specific nucleic acid amplification from infected organs. Animal use protocols were reviewed and approved by Institutional Animal Care and Use Committees in accordance with the Guide for the Care and Use of Laboratory Animals.
Sera were collected serially from experimentally infected animals over the course of infection. The number of serial sera ranged from 5 to 17 per animal. Only one serum sample was available from naturally infected animals. The ESAT-6 protein of M. tuberculosis was expressed as a polyhistidine-tagged fusion product in Escherichia coli and purified to near-homogeneity as previously described (3). Eight overlapping peptides (P1 to P8) spanning the full-length protein were also used. Peptides were synthesized as 24-mers (except P1, which was a 20-mer) with a sequence overlap of 14 amino acid residues (Fig. 1).
|
View larger version (7K): [in a new window] |
FIG. 1. Amino acid sequence of synthetic, overlapping peptides spanning the sequence of ESAT-6 protein. Each line represents a peptide sequence. Peptide names are listed at left.
|
25 CFU): all animals tested reacted with the P8 peptide, while only three reacted with the P1 peptide (data not shown).
![]() View larger version (28K): [in a new window] |
FIG. 2. Profiles of serum IgG antibody to ESAT-6 protein and ESAT-6-derived peptides in one rhesus macaque (A) and one cynomolgus macaque (B). IgG antibody against ESAT-6 protein and eight ESAT-6-derived, overlapping peptides (P1 to P8; see Fig. 1) was measured by ELISA in serum samples collected serially at times postinfection, as indicated. For coating of microtiter plates, recombinant protein or synthetic peptides were used at a concentration of 1.0 µg/ml (200 µl/well). ELISA was performed as previously described (1, 11). Data from two representative animals are shown, one animal per panel. Open symbols are used for antibody reactivity to peptides spanning the NH2-terminal half of ESAT-6; solid symbols correspond to peptides spanning the COOH-terminal half of the protein.
|
![]() View larger version (15K): [in a new window] |
FIG. 3. The antibody response to ESAT-6 peptides in experimentally infected animals. Antibody levels against ESAT-6 and ESAT-6-derived peptides were measured by ELISA in serum samples from 11 monkeys experimentally infected with M. tuberculosis. Cumulative numbers of animals whose sera gave OD450 readings above cutoff (responders) for each antigen are shown. For ESAT-6, the cutoff value was the mean plus 3 standard deviations of OD450 values obtained with sera from 51 negative-control, uninfected animals. For synthetic peptides, a cutoff of an OD450 of 0.3 was arbitrarily chosen, because the negative control sera gave extremely low readings when tested with synthetic peptides. Open bars represent numbers of responders for the indicated antigen by day 60 of infection; solid bars indicate the total number of responders for the indicated antigen.
|
We next tested ESAT-6-reactive sera from 20 nonhuman primates naturally infected with tuberculous mycobacteria. The levels of antibodies to the COOH-terminal half of ESAT-6 (P5 through P8 peptides) were higher than those of the antibodies directed against the P1-P4 region of ESAT-6 (Fig. 4A). Differences in mean optical densities at 450 nm (OD450s) were statistically significant between groups (mean OD450 = 0.4 [95% confidence interval: 0.175 to 0.625] for peptides P1 through P4; mean OD450 = 1.67 [95% confidence interval: 1.414 to 1.933] for P5, P6, and P8 peptides; P < 0.0001). Moreover, a greater number of sera reacted with the COOH-terminal half (peptides P5 to P8) than with the NH2-terminal half (peptides P1 to P4) of the protein (Fig. 4B). All sera reacted with peptides P5 and P8 together (data not shown).
![]() View larger version (17K): [in a new window] |
FIG. 4. The antibody response to ESAT-6 peptides in naturally infected animals. (A) Antibody levels against ESAT-6 and ESAT-6-derived peptides were measured by ELISA in serum samples from 20 monkeys naturally infected with M. tuberculosis or with M. bovis. Because of potential differences in the response to M. bovis versus M. tuberculosis infection, raw data are shown for the two groups of infected animals separately. Each data point represents one serum sample tested against the antigen indicated. Open symbols are used for data obtained with peptides spanning to the NH2-terminal half of ESAT-6; solid symbols correspond to peptides spanning the COOH-terminal half of the protein. (B) Specific antibody levels were not statistically different between the two groups of animals (with the exception of the intergroup analysis of the antibody levels to P8; P = 0.02). Thus, this panel shows the cumulative number of responders to ESAT-6 and ESAT-6-derived peptides in the two groups of naturally infected animals, calculated as described in the legend to Fig. 3.
|
We have previously shown that almost 90% of animals diagnosed at necropsy as having TB had serum IgG antibody against ESAT-6 (7). In relation to developing an ESAT-6-based serodiagnostic test for TB in monkeys, the observation that all ESAT-6-positive sera reacted to P5 plus P8 peptides makes it possible to consider use of synthetic peptides in lieu of full-length protein in order to reduce the costs of test manufacturing.
This work was supported in part by NIH grant AI36989 (to M.L.G.).
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»